High Blood Sugar in Leukemia: What It Means and What To Do

High blood sugar (hyperglycemia) can be common during leukemia treatment, and it deserves attention because it may increase the risk of infections and affect recovery. In many cases, it is temporary and related to treatment, but keeping it under control can help reduce complications.

Why Blood Sugar Rises in Leukemia

• Steroid medicines (like dexamethasone or prednisone), often used in leukemia regimens, can raise blood sugar even in people without diabetes. You may be asked to monitor glucose more frequently and adjust diabetes medication while on steroids. ^[1] People on steroid-containing regimens are advised to watch for increases in blood sugar and may need dose changes to their usual diabetes medicines. ^[2] Patient information for leukemia regimens repeatedly notes that steroids can cause an increase in blood sugar, and monitoring is recommended. ^[3]

• Other chemotherapy agents (for example, L‑asparaginase) can also trigger temporary diabetes or hyperglycemia by affecting insulin and glucagon balance. This drug-induced diabetes is typically managed with insulin during treatment and aims for modest, safe glucose targets to avoid both high and low sugars. [PM18] Older reports describe hyperglycemia during L‑asparaginase plus prednisone therapy due to reduced insulin and relatively high glucagon. [PM19]

Why It Matters

• Higher infection risk: Hyperglycemia can make infections more likely, especially during periods of low white blood cells (neutropenia). In children with ALL, hyperglycemia during induction has been linked to more infectious complications. [PM17] Adult and pediatric studies associate high glucose with increased infections and, in severe cases, higher sepsis-related mortality. [PM16] In pediatric ALL cohorts, overt hyperglycemia was tied to markedly higher rates of invasive fungal infection and sepsis-related death compared with normal glucose. [PM14]

• Worse short-term outcomes: In acute myeloid leukemia, hyperglycemia during hospitalization has been associated with higher in-hospital mortality. [PM13]

• Overall cancer care considerations: Managing blood sugar during cancer treatment can lower infection risk and support better tolerance of therapy. ^[4] Coexisting diabetes and cancer is common, and many people struggle with glucose control during treatment; coordinated care helps avoid hospitalizations and poor outcomes. ^{[5] [6]}

When To Be Concerned

• Persistent readings over 200 mg/dL (11.1 mmol/L) or symptoms like excessive thirst, frequent urination, fatigue, or blurry vision should prompt contact with your care team. Some oncology protocols even pause treatment if glucose is very high until it is brought down, and insulin may be needed. ^[7]

• Any fever (≥100.4°F / 38.0°C) during neutropenia is an emergency because infection risk is high; high glucose may compound that risk. Low white blood cell counts increase infection risk, and infections during neutropenia can be severe. ^[8]

What You Can Do

Work With Your Care Team

• Tell your oncologist about high readings and symptoms. Teams often plan closer glucose monitoring during steroid phases and adjust medications proactively. ^{[1] [2] [3]}
• Ask if you need temporary insulin. Insulin is the standard approach for treatment-induced diabetes, with safe target ranges typically aiming for premeal under ~140 mg/dL and postmeal 140–180 mg/dL to avoid both hyper- and hypoglycemia. [PM18]

Monitor and Record

• Check glucose more often on steroid days. Diabetic individuals are commonly advised to monitor closely while receiving corticosteroids in leukemia regimens. ^[9]
• Keep a log of readings, meds, meals, and symptoms; share it with your team to guide adjustments.

Supportive Habits

• Hydration and balanced meals: A balanced eating plan that fits diabetes care can help manage glucose and support nutrition during cancer treatment. ^[10]
• Infection prevention: Hand hygiene, food safety, and prompt reporting of fever are key during low counts. Neutropenia raises infection risk, so early detection matters. ^[11]

What To Expect Over Time

• Often temporary: Steroid- or chemotherapy-induced hyperglycemia is frequently short-lived and improves as those medicines are reduced or stopped. [PM18] People treated for hormone excess states show high rates of hyperglycemia improvement once the trigger is removed, illustrating the reversible nature of treatment-linked high glucose. ^[12]
• May recur with future steroid cycles: Those who had overt hyperglycemia during induction may experience it again in early continuation phases. [PM14]

Practical Targets and Safety

• Safe inpatient targets often aim for 140–180 mg/dL to avoid both extremes; individualized goals are set by your team. This “modest control” approach is common for drug‑induced diabetes management during ALL therapy. [PM18]
• Don’t overcorrect: In advanced cancer or during intense treatment, overly strict glucose lowering can raise the risk of hypoglycemia; a balanced, individualized plan is recommended. ^[13]

Key Takeaways

• High blood sugar during leukemia treatment is common and often due to steroids or certain chemo drugs. ^{[3] [1] [2]}
• It can increase infection risk and, in some settings, worsen short‑term outcomes, so it’s important to manage. [PM17] [PM16] [PM13] ^[4]
• Work with your team on monitoring and a practical plan sometimes including temporary insulin especially during steroid phases. [PM18] ^[9]
• Most treatment‑related hyperglycemia improves once the triggering medicines are reduced or stopped, but staying vigilant helps you stay safe. [PM18] ^[12]

궁금한 점 있으면 언제든 퍼슬리에 물어보세요.